[Depakine syrup in the treatment of therapy-resistant epilepsy].
Depakin syrup was given for several weeks in initial dose 300 mg/day with graded increase of the dose to 1200 mg/day to 11 patients aged 15-39 suffering from epilepsy and residual-organic affection of CNS with epileptic syndrome. A complete or partial discontinuation of the fits was achieved in 82% of the patients, primarily in those with partial and primary-generalized fits, partial fits with secondary generalization. It is concluded that depakin syrup treatment is justified in management of epilepsy, especially in the treatment-resistant cases.
Maksumova
E L
EL
Muzychenko
A P
AP
Sokolova
L V
LV
Zheleznova
E V
EV
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000008:administration & dosage*; D002908:Chronic Disease; D004351:Drug Resistance; D004569:Electroencephalography / Q000187:drug effects; D004827:Epilepsy / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D013997:Time Factors; D014635:Valproic Acid / Q000008:administration & dosage*
D000927:Anticonvulsants; D014635:Valproic Acid